{
    "pmcid": "10968798",
    "summary": "The paper \"Aptamers and Nanobodies as New Bioprobes for SARS-CoV-2 Diagnostic and Therapeutic System Applications\" provides a comprehensive review of the use of aptamers and nanobodies as molecular recognition elements (MREs) for the diagnosis and treatment of SARS-CoV-2. The review highlights the advantages of these bioprobes over traditional antibodies, focusing on their potential to enhance the sensitivity and specificity of diagnostic platforms and their therapeutic applications.\n\n### Key Insights on Nanobodies in SARS-CoV-2 Applications:\n\n1. **Structure and Advantages**:\n   - Nanobodies are derived from the variable domain of heavy-chain-only antibodies (VHH) found in camelids. They are the smallest functional antibody fragments (~15 kDa), significantly smaller than conventional antibodies (~150 kDa).\n   - Their small size allows for better tissue penetration and the ability to recognize cryptic epitopes that are inaccessible to larger antibodies.\n   - Nanobodies exhibit high stability, low immunogenicity, and can be produced cost-effectively in microbial systems like E. coli.\n\n2. **Binding Affinity and Stability**:\n   - Nanobodies have high binding affinities, often in the nanomolar to picomolar range, and maintain stability under extreme conditions, with melting temperatures around 67\u00b0C.\n   - The CDR3 loop in nanobodies is longer and more variable, contributing significantly to their binding affinity and specificity.\n\n3. **Production and Screening**:\n   - Phage display technology is the primary method for identifying antigen-specific nanobodies. This involves creating large libraries of phage particles displaying different nanobodies, followed by biopanning to select those with high affinity for the target antigen.\n   - Nanobodies can be engineered into multivalent constructs to enhance their binding and neutralizing capabilities.\n\n4. **Diagnostic Applications**:\n   - Nanobodies are used in various biosensing platforms, including ELISA, SPR, and nanopore sensors, to detect SARS-CoV-2 antigens like the spike (S) and nucleocapsid (N) proteins.\n   - They have been integrated into portable and rapid diagnostic devices, offering real-time detection capabilities.\n\n5. **Therapeutic Applications**:\n   - Nanobodies have been developed to neutralize SARS-CoV-2 by targeting the spike protein's receptor-binding domain (RBD), blocking its interaction with the human ACE2 receptor.\n   - Multivalent nanobodies have shown enhanced neutralization potency and are being explored for inhalation delivery to treat respiratory infections.\n\n6. **Engineering and Modifications**:\n   - Nanobodies can be engineered into multivalent forms, such as dimers or trimers, to increase their neutralizing potency and breadth against various SARS-CoV-2 variants.\n   - They can be combined with DNA nanostructures for enhanced spatial arrangement and multivalency, although this approach is less explored compared to aptamers.\n\n7. **Challenges and Future Directions**:\n   - Despite their advantages, challenges remain in ensuring the stability and reproducibility of nanobody-based diagnostics and therapeutics.\n   - Future research is focused on integrating nanobodies with advanced technologies like microfluidics and nanotechnology to develop portable, user-friendly diagnostic devices and exploring their dual function as both diagnostic and therapeutic agents.\n\nOverall, nanobodies represent a promising class of bioprobes for SARS-CoV-2 applications, offering advantages in terms of size, stability, and production efficiency. Their ability to be engineered into multivalent forms and integrated into various sensing platforms positions them as valuable tools in the ongoing fight against COVID-19 and potential future pandemics.",
    "title": "Aptamers and Nanobodies as New Bioprobes for SARS-CoV-2 Diagnostic and Therapeutic System Applications"
}